ACT34-CMI -- Adult Autologous CD34+ Cells

PHASE2CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2009

Conditions
Myocardial Ischemia
Interventions
BIOLOGICAL

CLBS14 (low-dose)

Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.

BIOLOGICAL

CLBS14 (high-dose)

Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.

BIOLOGICAL

placebo injection

Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.

Trial Locations (26)

10032

New York Presbyterian Hospital - Columbia University Medical Center, New York

10065

New York Presbyterian Hospital - Weill Cornell Medical College of Cornell University, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

20010

Washington Hospital Center, Washington D.C.

30342

Saint Joseph's Research Institute, Atlanta

32209

University of Florida Health Science Center, Jacksonville

32610

University of Florida Health Science Center, Gainesville

32803

Central Florida Cardiology Group, Orlando

33308

Holy Cross Hospital, Fort Lauderdale

35211

Cardiology PC, Birmingham

44106

University Hospitals Case Medical Center, Cleveland

45219

The Lindner Clinical Trial Center, Cincinnati

45267

University of Cincinnati Medical Center, Cincinnati

52242

University of Iowa Hospitals & Clinic, Iowa City

53223

Comprehensive Cardiovascular Care Group, Milwaukee

53792

University of Wisconsin Medical School, Madison

55407

Abbott Northwestern Hospital, Minneapolis

60611

Northwestern University Medical Center, Bluhm Cardiovascluar Institute, Chicago

60612

Rush University Medical Center, Chicago

85005

Arizona Heart Institute, Phoenix

85054

Mayo Clinic Hospital, Phoenix

92037

Scripps Memorial Hospital, La Jolla

94305

Stanford University Hospital and Clinics, Stanford

98122

Swedish Heart & Vascular - Swedish Medical Center, Seattle

02114

Massachusetts General Hospital, Boston

02135

Caritas Saint Elizabeth's Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT00300053 - ACT34-CMI -- Adult Autologous CD34+ Cells | Biotech Hunter | Biotech Hunter